Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | UTS2R | Q9UKP6 | 16/20 | 0.37 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.35 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL637837 | 0.90 | SMN1; SMN2 (0.36) | SMN1; SMN2LMNAHTTUTS2RABCB11 | |
| SCHEMBL2231120 | 0.88 | UTS2R (0.40) | UTS2RCYP26A1 | |
| SCHEMBL637135 | 0.86 | CCKBR (0.42) | HTTUTS2RPPARA | |
| SCHEMBL2230625 | 0.83 | UTS2R (0.40) | SMN1; SMN2LMNAHTTUTS2R | |
| SCHEMBL2231738 | 0.83 | UTS2R (0.42) | UTS2R | |
| SCHEMBL2233808 | 0.82 | UTS2R (0.41) | SMN1; SMN2LMNAHTTUTS2R | |
| SCHEMBL2233092 | 0.78 | ATM (0.44) | SMN1; SMN2LMNAABCB11CYP1A2CYP3A4 | |
| SCHEMBL2231327 | 0.78 | UTS2R (0.47) | UTS2R | |
| SCHEMBL2230681 | 0.78 | UTS2R (0.42) | UTS2R | |
| SCHEMBL6684836 | 0.78 | SMN1; SMN2 (0.48) | SMN1; SMN2UTS2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2354120-A1 | Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof | XenoPort, Inc. (US) | 2011-08-10 | — | — | EP | disclosed |
| US-20090118365-A1 | Use of Prodrugs of GABA B Agonists for Treating Neuropathic and Musculoskeletal Pain | XENOPORT, INC (US) | 2009-05-07 | — | — | US | disclosed |
| WO-2008157408-A2 | USE OF PRODRUGS OF GABA ANALOGS, ANTISPASTICITY AGENTS, AND PRODRUGS OF GABA B RECEPTOR AGONISTS FOR TREATING SPASTICITY | XENOPORT, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118365-A1 | Use of Prodrugs of GABA B Agonists for Treating Neuropathic and Musculoskeletal Pain | GABBR1, GABBR2, GABRB2 | SMN1; SMN2 56/4885LMNA 2460/4885HTT 4441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.